HRMY
NASDAQHarmony Biosciences Holdings Inc.
News · 26 weeks52+550%
2025-10-262026-04-19
Mix3190d
- Insider10(32%)
- SEC Filings7(23%)
- Other6(19%)
- Earnings3(10%)
- Analyst3(10%)
- Leadership2(6%)
Latest news
25 items- PRHarmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 7, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-274-8461 (domestic) or 203-518-9814 (international or alternate), and reference passcode HRMYQ126. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Bioscien
- PRHarmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual MeetingHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will present encore open-label extension data from the company's investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment of Dravet syndrome at the 2026 American Academy of Neurology Annual Meeting being held April 18 – 22 in Chicago, IL. The ARGUS trial is currently enrolling, and more information about the trial can be found at argustrial.com. Poster presentation details are listed below: Abstract Title: ARGUS: A Study of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Participants with Dravet Syndrome (DS): Preliminary Results from the Open-lab
- SECHarmony Biosciences Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
- PRHarmony Biosciences Appoints Glenn Reicin as Chief Financial OfficerCOMPANY REITERATES ITS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION IN WAKIX SALES Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced the appointment of Glenn Reicin as Chief Financial Officer, effective immediately, supporting Harmony's continued focus on strategic growth, financial strength, and long‑term value creation. Harmony is also reiterating its 2026 net product revenue guidance of $1.0 to $1.04 billion. Mr. Reicin is a seasoned biopharmaceutical executive with extensive experience across publicly traded and privately held companies, guiding them through key growth inflection points. With his experience as a sell-side analyst, investor and biotech CFO, he brings
- INSIDERSEC Form 4 filed by Zaeske Adam H.4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- INSIDERSEC Form 4 filed by Anastasiou Peter4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- INSIDERSEC Form 4 filed by Ignelzi Troy A.4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ignelzi Troy A.3 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
- SECSEC Form DEFA14A filed by Harmony Biosciences Holdings Inc.DEFA14A - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
- SECSEC Form DEF 14A filed by Harmony Biosciences Holdings Inc.DEF 14A - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
- SECHarmony Biosciences Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
- PRHarmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its BoardAppointments support Harmony's next phase of growth and long‑term value creation Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of Directors, including the appointment of Troy Ignelzi as a director and the nomination of Geno J. Germano as a director for election at Harmony's 2026 Annual Meeting of Shareholders. Mr. Anastasiou previously served on Harmony Biosciences' Board of Directors, where he contributed strategic insight across the business during a period of continued growth and operational evolution. He brings more than three decades of experience building and leading biotechn
- PRHarmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare ConferenceHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that Harmony's management team will participate in a fireside chat at the upcoming 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026, at 9:30 a.m. ET. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Har
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Harmony Biosciences Holdings Inc.SCHEDULE 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
- PRHarmony Biosciences to Participate in Upcoming Investor ConferencesHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will attend the following upcoming investor conferences. Leerink Partners Global Healthcare Conference Date: March 9, 2026 Location: Miami, FL UBS Biotech Summit Date: March 9, 2026 Location: Miami, FL Barclays 28th Annual Global Healthcare Conference Date: March 10, 2026 Location: Miami, FL About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to
- SECSEC Form 10-K filed by Harmony Biosciences Holdings Inc.10-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
- SECHarmony Biosciences Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
- PRHarmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 BillionWAKIX 2025 Net Revenue of $868.5 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy Recently Completed Settlements with 3 Additional Generic Filers Toward Goal of Securing WAKIX Franchise Pitolisant GR NDA Submission on Track for Q2 2026; Extends the Pitolisant Franchise into the 2040s Exploring New Opportunities to Broaden the Pitolisant Franchise Beyond Orphan/Rare into Larger CNS Indications Potential Best-In-Class Orexin-2 Agonist (BP1.15205) Phase 1 Trial Ongoing; Clinical Data Expected in Mid-2026 Conference Call and Webcast Today at 8:30 a.m. ET Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced ear
- ANALYSTHarmony Biosciences downgraded by Deutsche BankDeutsche Bank downgraded Harmony Biosciences from Buy to Hold
- ANALYSTHarmony Biosciences downgraded by TruistTruist downgraded Harmony Biosciences from Buy to Hold
- PRHarmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric NarcolepsyHarmony Biosciences (NASDAQ:HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for WAKIX® (pitolisant) tablets for the treatment of cataplexy in pediatric patients 6 years of age and older with narcolepsy. WAKIX is now the first-and-only FDA-approved non-scheduled treatment for pediatric and adult narcolepsy patients with or without cataplexy. "We are excited to achieve this important milestone for pediatric narcolepsy patients who experience cataplexy," said Kumar Budur, M.D., M.S., Chief Medical and Scientific Officer of Harmony Biosciences. "With this approval, clinicians now have the option to prescribe WAKI
- ANALYSTUBS resumed coverage on Harmony Biosciences with a new price targetUBS resumed coverage of Harmony Biosciences with a rating of Neutral and set a new price target of $46.00
- PRHarmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on February 24, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-274-7083 (domestic) or 203-518-9786 (international), and reference passcode HRMYQ425. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Har
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Harmony Biosciences Holdings Inc.SCHEDULE 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
- INSIDERCHIEF FINANCIAL OFFICER Kapadia Sandip sold $139,171 worth of shares (3,746 units at $37.15), decreasing direct ownership by 13% to 24,521 units (SEC Form 4)4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)